内蒙古启动蒙医药专利池计划

2018-12-13 勿日汗 新华网

近日,内蒙古自治区启动蒙医药专利池计划,让蒙医药专利技术转移转化交易更加有“序”。据了解,这是我国首个专门为蒙医药产业和专利技术实施知识产权保护的专利运营池。蒙医药专利池计划将多个不同领域蒙医药专利权人的多项专利成果集中起来,形成联盟。联盟成员之间的专利产品可以互相授权使用,也可以集中授权给第三方使用,改变了以往蒙医药生产企业开发新产品需要向不同领域的专利权人分别请求许可的局面。专家指出,多年来,

近日,内蒙古自治区启动蒙医药专利池计划,让蒙医药专利技术转移转化交易更加有“序”。据了解,这是我国首个专门为蒙医药产业和专利技术实施知识产权保护的专利运营池。

蒙医药专利池计划将多个不同领域蒙医药专利权人的多项专利成果集中起来,形成联盟。联盟成员之间的专利产品可以互相授权使用,也可以集中授权给第三方使用,改变了以往蒙医药生产企业开发新产品需要向不同领域的专利权人分别请求许可的局面。

专家指出,多年来,作为我国四大民族医药体系之一的蒙医药知识产权保护状况令人担忧,专利数量少、专利保护意识不强、缺乏品牌战略思想、只会使用而不懂保护等普遍存在的问题已经严重制约蒙医药的技术创新和产业发展。

目前,我国有近600件蒙医药相关专利,专利申请人300多人。蒙医药可转化为专利的对象包括蒙药材、蒙药复方制剂等。

据了解,蒙医药专利池将全面对接全国蒙医药研究机构、高校、企业以及民间从业人员,广泛征集蒙医药专利入池,整理、盘活和优化高质量蒙医药技术专利,并全程对池内的技术专利进行知识产权保护的专业指导。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811515, encodeId=7a16181151553, content=<a href='/topic/show?id=d5e588316c2' target=_blank style='color:#2F92EE;'>#蒙医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88316, encryptionId=d5e588316c2, topicName=蒙医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Tue Feb 19 21:07:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898744, encodeId=a01b1898e4403, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Dec 18 07:07:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409743, encodeId=dfaa1409e43a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 15 05:07:00 CST 2018, time=2018-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811515, encodeId=7a16181151553, content=<a href='/topic/show?id=d5e588316c2' target=_blank style='color:#2F92EE;'>#蒙医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88316, encryptionId=d5e588316c2, topicName=蒙医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Tue Feb 19 21:07:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898744, encodeId=a01b1898e4403, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Dec 18 07:07:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409743, encodeId=dfaa1409e43a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 15 05:07:00 CST 2018, time=2018-12-15, status=1, ipAttribution=)]
    2018-12-18 xugumin
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811515, encodeId=7a16181151553, content=<a href='/topic/show?id=d5e588316c2' target=_blank style='color:#2F92EE;'>#蒙医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88316, encryptionId=d5e588316c2, topicName=蒙医)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Tue Feb 19 21:07:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898744, encodeId=a01b1898e4403, content=<a href='/topic/show?id=e12930529ee' target=_blank style='color:#2F92EE;'>#内蒙古#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30529, encryptionId=e12930529ee, topicName=内蒙古)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Tue Dec 18 07:07:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409743, encodeId=dfaa1409e43a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Dec 15 05:07:00 CST 2018, time=2018-12-15, status=1, ipAttribution=)]
    2018-12-15 cathymary